Zealand Pharma A/S - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Zealand Pharma A/S - Product Pipeline Review - 2016', provides an overview of the Zealand Pharma A/S's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Zealand Pharma A/S, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Zealand Pharma A/S - The report provides overview of Zealand Pharma A/S including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Zealand Pharma A/S's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Zealand Pharma A/S's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Zealand Pharma A/S's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Zealand Pharma A/S - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Zealand Pharma A/S's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Zealand Pharma A/S Snapshot 5 Zealand Pharma A/S Overview 5 Key Information 5 Key Facts 5 Zealand Pharma A/S - Research and Development Overview 6 Key Therapeutic Areas 6 Zealand Pharma A/S - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Pipeline Products - Out-Licensed Products 12 Out-Licensed Products/Combination Treatment Modalities 13 Zealand Pharma A/S - Pipeline Products Glance 14 Zealand Pharma A/S - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Zealand Pharma A/S - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Zealand Pharma A/S - Drug Profiles 17 ZP-1848 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 ZP-4207 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 ZP-2929 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Synthetic Peptide for Diabetes and Obesity 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Synthetic Peptides for Undisclosed Indications 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ZP-3022 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ZPDI-70 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 ZPGG-23 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 ZPGG-72 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 ZPI-98 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Zealand Pharma A/S - Pipeline Analysis 27 Zealand Pharma A/S - Pipeline Products by Target 27 Zealand Pharma A/S - Pipeline Products by Route of Administration 28 Zealand Pharma A/S - Pipeline Products by Molecule Type 29 Zealand Pharma A/S - Pipeline Products by Mechanism of Action 30 Zealand Pharma A/S - Recent Pipeline Updates 31 Zealand Pharma A/S - Dormant Projects 34 Zealand Pharma A/S - Locations And Subsidiaries 35 Head Office 35 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Zealand Pharma A/S, Key Information 5 Zealand Pharma A/S, Key Facts 5 Zealand Pharma A/S - Pipeline by Indication, 2016 7 Zealand Pharma A/S - Pipeline by Stage of Development, 2016 8 Zealand Pharma A/S - Monotherapy Products in Pipeline, 2016 9 Zealand Pharma A/S - Partnered Products in Pipeline, 2016 10 Zealand Pharma A/S - Partnered Products/ Combination Treatment Modalities, 2016 11 Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2016 12 Zealand Pharma A/S - Out-Licensed Products/ Combination Treatment Modalities, 2016 13 Zealand Pharma A/S - Phase II, 2016 14 Zealand Pharma A/S - Phase I, 2016 15 Zealand Pharma A/S - Preclinical, 2016 16 Zealand Pharma A/S - Pipeline by Target, 2016 27 Zealand Pharma A/S - Pipeline by Route of Administration, 2016 28 Zealand Pharma A/S - Pipeline by Molecule Type, 2016 29 Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2016 30 Zealand Pharma A/S - Recent Pipeline Updates, 2016 31 Zealand Pharma A/S - Dormant Developmental Projects,2016 34
List of Figures
Zealand Pharma A/S - Pipeline by Indication, 2016 7 Zealand Pharma A/S - Pipeline by Stage of Development, 2016 8 Zealand Pharma A/S - Monotherapy Products in Pipeline, 2016 9 Zealand Pharma A/S - Partnered Products in Pipeline, 2016 10 Zealand Pharma A/S - Out-Licensed Products in Pipeline, 2016 12 Zealand Pharma A/S - Pipeline by Target, 2016 27 Zealand Pharma A/S - Pipeline by Route of Administration, 2016 28 Zealand Pharma A/S - Pipeline by Molecule Type, 2016 29 Zealand Pharma A/S - Pipeline Products by Mechanism of Action, 2016 30
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.